AlloVir, Inc. announced its financial results for Q4 and 2022, as well as positive final results from a Phase 2 study of posoleucel for the treatment of BK viremia in adult kidney transplant recipients.
AI Assistant
KALARIS THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.